Financials in USD. Standardized financial statements.
A compact view of how Ono Pharmaceutical Co., Ltd. turns revenue into operating income and net income.
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $519.03B | $486.87B | $502.67B | $447.19B | $361.36B | $309.28B | $292.42B | $288.63B | $261.84B | $244.80B |
| Revenue Growth? | +6.6% | -3.1% | +12.4% | +23.8% | +16.8% | +5.8% | +1.3% | +10.2% | +7.0% | 0.0% |
| Cost of Revenue? | $142.61B | $147.95B | $127.13B | $110.06B | $93.51B | $85.57B | $79.06B | $83.83B | $65.39B | $65.52B |
| Gross Profit? | $376.42B | $338.92B | $375.55B | $337.13B | $267.85B | $223.71B | $213.36B | $204.81B | $196.44B | $179.27B |
| Gross Margin? | +72.5% | +69.6% | +74.7% | +75.4% | +74.1% | +72.3% | +73.0% | +71.0% | +75.0% | +73.2% |
| Operating Expenses? | $272.44B | $279.17B | $212.44B | $184.83B | $152.94B | $131.61B | $135.87B | $142.79B | $135.76B | $106.99B |
| Operating Income? | $103.99B | $59.75B | $163.10B | $152.29B | $114.91B | $92.10B | $77.49B | $62.01B | $60.68B | $72.28B |
| EBITDA? | $141.98B | $91.54B | $178.44B | $167.50B | $128.54B | $116.85B | $91.92B | $74.20B | $67.39B | $83.92B |
| Income Before Tax | $93.24B | $59.33B | $163.73B | $143.53B | $105.03B | $100.89B | $79.70B | $65.14B | $63.92B | $74.54B |
| Income Tax Expense | $22.89B | $9.16B | $35.69B | $30.62B | $24.34B | $25.39B | $19.81B | $13.46B | $13.53B | $18.50B |
| Net Income? | $70.21B | $50.05B | $127.98B | $112.72B | $80.52B | $75.42B | $59.70B | $51.54B | $50.28B | $55.79B |
| EPS? | $150.19 | $106.55 | $266.61 | $230.85 | $162.19 | $151.11 | $118.47 | $100.25 | $97.00 | $105.27 |
| Diluted EPS? | $148.60 | $106.41 | $266.60 | $230.79 | $162.16 | $151.09 | $118.45 | $100.24 | $96.99 | $105.26 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality